# Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

> **NCT00106301** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 2 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Prostatic Neoplasms

## Interventions

- **DRUG:** FK228 (romidepsin)

## Key facts

- **NCT ID:** NCT00106301
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-01
- **Primary completion:** 2006-09-01
- **Final completion:** 2006-09-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106301, "Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00106301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*